Selected Publication:

SHR Neuro Cancer Cardio Lipid Metab Microb

Schicho, R; Storr, M.
Alternative targets within the endocannabinoid system for future treatment of gastrointestinal diseases.
CAN J GASTROENTEROL. 2011; 25(7): 377-383. Doi: 10.1155/2011/953975 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

Leading authors Med Uni Graz

Schicho Rudolf

Altmetrics:

Dimensions Citations:

Plum Analytics:

Scite (citation analytics):

Abstract:

Many beneficial effects of herbal and synthetic cannabinoids on gut motility and inflammation have been demonstrated, suggesting a vast potential for these compounds in the treatment of gastrointestinal disorders. These effects are based on the so-called 'endocannabinoid system' (ECS), a cooperating network of molecules that regulate the metabolism of the body's own and of exogenously administered cannabinoids. The ECS in the gastrointestinal tract quickly responds to homeostatic disturbances by de novo synthesis of its components to maintain homeostasis, thereby offering many potential targets for pharmacological intervention. Of major therapeutic interest are nonpsychoactive cannabinoids or compounds that do not directly target cannabinoid receptors but still possess cannabinoid-like properties. Drugs that inhibit endocannabinoid degradation and raise the level of endocannabinoids are becoming increasingly promising alternative therapeutic tools to manipulate the ECS.

Find related publications in this database (using NLM MeSH Indexing)

Animals -

Colonic Neoplasms - drug therapy

Endocannabinoids - physiology

Gastrointestinal Diseases - drug therapy

Humans -

Inflammatory Bowel Diseases - drug therapy

Irritable Bowel Syndrome - drug therapy

Receptors, Cannabinoid - drug effects

Find related publications in this database (Keywords)

Cannabinoid receptors

Colon cancer

Emesis

Inflammatory bowel disease

Irritable bowel syndrome

Rimonabant

THC

© Med Uni Graz • Imprint